Nebenwirkungen · Jevtana
JEVTANA 60 mg concentrate and solvent for solution for infusion. · Abschnitt 4.8 · PDF-Seite 11
HOS-124053 · Präparat HOS-095771
Cardiac disorders and arrhythmias In the pooled analysis, cardiac events were reported in 5.5% of the patients of which 1.1% had grade ≥3 cardiac arrhythmias. The incidence of tachycardia on cabazitaxel was 1.0%, of which less than 0.1% were grade ≥3. The incidence of atrial fibrillation was 1.3%. Cardiac failure events were reported for 2 patients (0.2%), one of which resulted in a fatal outcome. Fatal ventricular fibrillation was reported in 1 patient (0.3%), and cardiac arrest in 3 patients (0.5%). None were considered related by the investigator.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-30T13:04:00Z · SHA-256 4c1eff0507207d5beb179217fec464186ac3bc1330fa052cff48922b617d3c37 · Passage defa4c5156e04d1f648d7d4498651d08eb36ce830be2670bd8744ce91d7483a1 · Zeichen 14240–14796 im Abschnitt